MA31521B1 - Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central - Google Patents

Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central

Info

Publication number
MA31521B1
MA31521B1 MA32515A MA32515A MA31521B1 MA 31521 B1 MA31521 B1 MA 31521B1 MA 32515 A MA32515 A MA 32515A MA 32515 A MA32515 A MA 32515A MA 31521 B1 MA31521 B1 MA 31521B1
Authority
MA
Morocco
Prior art keywords
nervous system
diseases
central
dihydropenzo
dioxin
Prior art date
Application number
MA32515A
Other languages
Arabic (ar)
English (en)
Inventor
Belle David Din
Patrik Holm
Arto Karljalainen
Arto Tolvanen
Gerd Wohlfahrt
Petteri Rummakko
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39884455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31521(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of MA31521B1 publication Critical patent/MA31521B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (i). Dans ladite formule, x, z, r1-r4 et m sont tels que définis dans les revendications. Lesdits composés présentent une activité antagoniste envers les alpha2c, et peuvent par conséquent être utilisés pour traiter des maladies et des états du système nerveux périphérique et du système nerveux central (snc).
MA32515A 2007-07-20 2010-01-15 Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central MA31521B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95098307P 2007-07-20 2007-07-20
PCT/FI2008/000090 WO2009013390A1 (fr) 2007-07-20 2008-07-18 Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central

Publications (1)

Publication Number Publication Date
MA31521B1 true MA31521B1 (fr) 2010-07-01

Family

ID=39884455

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32515A MA31521B1 (fr) 2007-07-20 2010-01-15 Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central

Country Status (31)

Country Link
US (3) US8492549B2 (fr)
EP (1) EP2176252B1 (fr)
JP (1) JP5460590B2 (fr)
KR (1) KR101535059B1 (fr)
CN (1) CN101842369B (fr)
AR (1) AR069271A1 (fr)
AU (1) AU2008278924B2 (fr)
BR (1) BRPI0814529B8 (fr)
CA (1) CA2693804C (fr)
CL (1) CL2008002114A1 (fr)
CO (1) CO6331473A2 (fr)
CY (1) CY1115789T1 (fr)
DK (1) DK2176252T3 (fr)
EA (1) EA017554B1 (fr)
ES (1) ES2502215T3 (fr)
GE (1) GEP20125538B (fr)
HR (1) HRP20141156T1 (fr)
IL (1) IL202964A (fr)
MA (1) MA31521B1 (fr)
MY (1) MY153872A (fr)
NZ (1) NZ582432A (fr)
PE (1) PE20090890A1 (fr)
PL (1) PL2176252T3 (fr)
PT (1) PT2176252E (fr)
RS (1) RS53571B1 (fr)
SI (1) SI2176252T1 (fr)
TN (1) TN2010000029A1 (fr)
TW (1) TWI457122B (fr)
UA (1) UA100695C2 (fr)
WO (1) WO2009013390A1 (fr)
ZA (1) ZA201000314B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
DK2271638T3 (da) * 2008-04-29 2011-11-28 Nsab Af Neurosearch Sweden Ab Modulatorer af dopaminneurotransmission
WO2009133107A1 (fr) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulateurs de la neurotransmission de la dopamine
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US8822679B2 (en) * 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
US9518034B2 (en) 2013-10-14 2016-12-13 California Institute Of Technology Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CN108752212B (zh) * 2015-03-06 2024-03-12 北京大学 9-脱羧迷迭香酸类似物及其合成方法和应用
CN107922373A (zh) 2015-03-27 2018-04-17 加利福尼亚技术学院 使用低催化剂浓度和稳定的预催化剂的不对称催化脱羧烷基烷基化
AR104882A1 (es) * 2015-06-05 2017-08-23 Orion Corp DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C
WO2017156239A1 (fr) 2016-03-11 2017-09-14 California Institute Of Technology Compositions et procédés d'acylation de lactames
EP3478676A1 (fr) 2016-06-29 2019-05-08 Orion Corporation Dérivés de benzodioxane et leur utilisation pharmaceutique
CN110662541B (zh) * 2017-03-12 2023-02-10 王晓冬 多环胺作为阿片受体调节剂
US10358422B2 (en) 2017-11-01 2019-07-23 California Institute Of Technology Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
GB201801130D0 (en) * 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
EP3856183A1 (fr) * 2018-09-25 2021-08-04 Bayer Aktiengesellschaft Antagonistes de récepteur alpha 2-adrénergiques de sous-type c (alpha-2c) pour le traitement de l'apnée du sommeil
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
MX2024008523A (es) 2022-01-07 2024-07-19 Bayer Ag Antagonistas del adrenoceptor a2 subtipo c para el tratamiento de la apnea del sue?o.
KR102776660B1 (ko) * 2022-01-25 2025-03-04 재단법인 한국파스퇴르연구소 벤조다이옥세인 유도체 화합물 및 이의 의약 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) * 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
GB1411531A (en) * 1972-10-24 1975-10-29 Lafon Labor Amino derivatives of 1,4-benzodioxan
JPS5163193A (ja) 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US4039676A (en) * 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
HU181575B (en) 1980-10-03 1983-10-28 Richter Gedeon Vegyeszet Process for preparing 3-chloro-propyl-malonic acid ester and cyano-acetic acid ester derivatives
FR2525600A1 (fr) 1982-04-21 1983-10-28 Bouchara Emile Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
DD250930A1 (de) 1986-06-08 1987-10-28 Isis Chemie Zwickau Veb Verfahren zur herstellung neuer tetrahydroisochinolinderivate
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
JPH04500075A (ja) 1988-08-16 1992-01-09 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺菌性ベンゾジオキサンアミン誘導体
CA2104873C (fr) 1991-02-26 2000-05-23 James N. Campbell Compositions et methodes pour le traitement de la douleur entretenue par le systeme sympathique
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
FR2744451B1 (fr) * 1996-02-01 1998-04-24 Pf Medicament Nouvelles imidazolidinones, pyrimidinones, et 1,3-diazepin-2 -ones, leur preparation et leurs applications en therapeutique
WO1998050359A1 (fr) 1997-05-06 1998-11-12 Novo Nordisk A/S Nouveaux composes heterocycliques
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
BR9813381A (pt) 1997-12-04 2000-10-03 Allergan Sales Inc "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c"
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
AU2001290873B2 (en) * 2000-09-11 2006-07-27 Sepracor Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
DE60316672T2 (de) 2002-04-03 2008-07-17 Orion Corp. Polycyclische verbindungen als potente alpha2-adrenoceptor antagonisten
WO2004067513A1 (fr) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonistes pour recepteurs alpha-2 adrenergiques
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
JP5163193B2 (ja) 2008-03-13 2013-03-13 セイコーエプソン株式会社 プリンタシステム及びプリンタシステムにおける制御方法

Also Published As

Publication number Publication date
PT2176252E (pt) 2014-12-03
HRP20141156T1 (hr) 2015-01-16
BRPI0814529B8 (pt) 2021-05-25
ZA201000314B (en) 2010-10-27
US8697723B2 (en) 2014-04-15
CN101842369A (zh) 2010-09-22
SI2176252T1 (sl) 2014-12-31
BRPI0814529A2 (pt) 2015-01-27
US20130281486A1 (en) 2013-10-24
WO2009013390A1 (fr) 2009-01-29
TW200908961A (en) 2009-03-01
US8492549B2 (en) 2013-07-23
PE20090890A1 (es) 2009-07-08
MY153872A (en) 2015-03-31
CY1115789T1 (el) 2017-01-25
EP2176252B1 (fr) 2014-09-03
RS53571B1 (sr) 2015-02-27
AU2008278924A1 (en) 2009-01-29
CA2693804A1 (fr) 2009-01-29
BRPI0814529B1 (pt) 2019-09-17
EA201070169A1 (ru) 2010-06-30
EA017554B1 (ru) 2013-01-30
TWI457122B (zh) 2014-10-21
AU2008278924B2 (en) 2013-09-26
AR069271A1 (es) 2010-01-13
HK1148530A1 (en) 2011-09-09
PL2176252T3 (pl) 2015-04-30
KR20100044220A (ko) 2010-04-29
CA2693804C (fr) 2015-11-24
EP2176252A1 (fr) 2010-04-21
US20140179926A1 (en) 2014-06-26
US20120035210A9 (en) 2012-02-09
CN101842369B (zh) 2014-01-22
US20100216836A1 (en) 2010-08-26
UA100695C2 (ru) 2013-01-25
JP5460590B2 (ja) 2014-04-02
ES2502215T3 (es) 2014-10-03
CO6331473A2 (es) 2011-10-20
IL202964A (en) 2013-12-31
GEP20125538B (en) 2012-05-25
US8809536B2 (en) 2014-08-19
TN2010000029A1 (en) 2011-09-26
DK2176252T3 (en) 2014-12-08
JP2010534197A (ja) 2010-11-04
NZ582432A (en) 2012-03-30
CL2008002114A1 (es) 2009-04-03
KR101535059B1 (ko) 2015-07-24

Similar Documents

Publication Publication Date Title
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
MA31766B1 (fr) Composés organiques
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
MA27933A1 (fr) Inhibiteurs de l'activite de akt
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
EA201000314A1 (ru) 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
TN2010000029A1 (en) 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA38091B1 (fr) Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
MA30540B1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives.
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
MA33916B1 (fr) Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
UA81464C2 (en) NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS